AMARIN CORPORATION SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Claims On Behalf Of Shareholders Of Amarin Corporation

Levi & Korsinsky is investigating the Board of Directors of Amarin Corporation plc (“Amarin” or the “Company”) (NasdaqGM: AMRN) for possible violations of federal securities laws.

Click here to learn more about the investigation: http://zlk.9nl.com/amarin-amrn/ or call: 877-363-5972. There is no cost or obligation to you.

On October 11, 2013, Amarin shares fell more than 20% to close at $5.09 after the Food & Drug Administration released its briefing documents for the October 16, 2013 advisory committee review of Amarin’s application to expand the use of its drug Vascepa. The FDA briefing documents raised questions about the mineral oil placebo potentially negatively impacting the control group data and consequentially overstating Vascepa’s effectiveness.

If you own Amarin stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/amarin-amrn/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Amarin (AMRN) Stock Drops After Pricing Public Offering

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves